Dental DiseaseNCT02814799
Effects of the Bone Tissue on the Haemostasis
An observational study of Dental Disease, run by CHU de Reims at 1 site in France.
Trial summary
The research for a haemostasis and for an effective osseous healing are a major stake in oral surgery. The use of glues of fibrin, amplifying the polymerization of the fibrin during the haemostasis is known to reduce the risk of post-operative bruise and accelerate the healing but these glues present the inconvenience… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Dental Disease
- What is being tested?
- bone removal
- How many people
- 30 participants
- Where
- 1 siteFrance
- Study dates
- May 2013to Dec 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The inclusive patients will be all the patients requiring dental extractions with bone removal, taken care in the department of odontology of the CHU of Reims and agreeing to participate in the study. Only these patients form the group of observed patients. The duration of participation of the patient in the study is punctual, the time of the osseous taking.
Inclusions criteria
Will be included in this study:
- The patients requiring dental extractions with bone removal
- The patients agreeing to participate in the search
Exclusions criteria
Will not be included in this study:
- Minor patients.
- Patients protected by the law.
Trial locations and contacts
1 site in 1 country.
Sébastien LAURENCE contact
France1 site, 1 recruiting
- Recruiting
Chu Reims
France, Reims, 51092
Damien JOLLY, 326788472 ext. 33, djolly@chu-reims.fr
About this study
Official title: Study of the Effects of the Bone Tissue on the Generation of Thrombine
The research for a haemostasis and for an effective osseous healing are a major stake in oral surgery. The use of glues of fibrin, amplifying the polymerization of the fibrin during the haemostasis is known to reduce the risk of post-operative bruise and accelerate the healing but these glues present the inconvenience to be by-products of the blood, not devoid of infectious risk.
Read the detailed description
Thrombinography is a functional exploration of the haemostasis allowing the characterization of the kinetics and the amount of thrombin. Its principle bases on the recording of the activity of the in vitro thrombin, by fluorometry. The formed thrombin leads a signal by activation of the fluorogenic substrates. The intensity of the received signal is correlated in the generation of thrombin by comparative measure of the fluorescence of a standard sample of thrombinic activity known. The analysis is realized by a specific software: Thrombinoscope®. The used reactional environment is a poor Plasma in platelet (PPP).
The software defines the quantity of thrombin generated (nM) according to time (in minute) and calculate the values of:
- Lag time: latent period before the beginning of synthesis of thrombin.
- Start Tail: duration of the process.
- Peak: peak of thrombin, is the maximal rate of generated thrombin.
- ETP (Endogenous Thrombin Potential): area under the curve representing the total potential of generation of thrombin.
- Time to Peak: time required to reach the peak of thrombin. It is these values which will serve as criteria of evaluation for our study.
Osseous type
The cancellous bone is majority in the short bones and the epiphyses of the long bones. It is crisp, constituted by fine osseous patches arranged in a not concentric way around wide open cavities, filled with bone marrow rich in cells, and richly vascularized. The cancellous bone is surrounded with compact bone. At the level of tooth sockets, this osseous type is found in particular at the level of interradicular septa.
The compact bone establishes the cortical. It is dense, consisted of systems of Havers. Every system is formed by a reduced central channel containing some vascularized connective tissue, and thick, concentric osseous small strips, in and between which prepares ostéocytes. This osseous type is situated at the alveolar level in the external part.
Inhibitors
To verify the possible ways involved in the thrombin formation, the investigators shall use specific inhibitors of these likely ways of activation:
- An inhibitor of the extrinsic way of the coagulation: an antibody anti tissue factor.
- An inhibitor of the intrinsic way of the coagulation: the bovine aprotinin.
- An inhibitor of phospholipids: the annexin V. Methodology of the Research
Plan of investigation
- Information of the eligible patients for the study (patients requiring dental extractions with bone removal) concerning the methods and the objectives of the research by means of the information note.
- If the patient agrees to participate in the study, realization of osseous takings and conditioning of the osseous takings for freezing in the liquid nitrogen.
- Put in touch by the osseous takings with some plasma (from pools of plasma used in laboratory for the calibration of the various automatous) and measure of the genesis of thrombin by thrombinography.
To make this measure, the osseous fragments will be put down at the bottom of the wells of the microplate then 10µL of buffer HBS will be added. The fragmentation of the osseous takings will be realized by means of a sterile material and by limiting the time of manipulation except environment.
Every sample will be handled triplicate there. Two wells will be dedicated to the standard thrombin (20µL). Two controls will be used: - positive control: 10µL of tissue factor, in the concentration of 1 or 5 pM and 10µL of PPL in the dilution of 1/100 will be used.
- Negative control: 20µL of physiological salt solution will be used. Eighty microliters of plasma are going to be put down in each of the wells. Fifty microliters of fluorescent substratum will be added to the mixture buffer - substratum fluorogenic beforehand prepared and the device is going to distribute 20µL some mixture in each of the wells, thus containing in the end 120µL.
The measures were made every 20 seconds during 60 minutes by the Fluoroskan Ascent Reader. The Thrombinoscope softwar® (Version 3.0.0.29, Maastricht) converts the intensity of fluorescence nM of thrombin according to the time.
The results of the measures will be grouped in cancellous bone, compact bone, control FT1pM, control FT5pM and secondarily averaged.
According to the obtained results, samples (compact and\or cancellous) positive for the genesis of thrombin will be analyzed in the presence of specific inhibitors of the various possible ways of activation of the coagulation. Calibrations will be made to choose the most appropriate concentration in inhibitors.
Logistics of the study
An information concerning the objectives and the modalities of the study will be given to every patient benefiting from one or several dental extractions with bone removal. If the patient agrees to participate in the study (oral agreement), the osseous taking, associated automatically with the dental extraction will be kept.
After taking, the osseous fragments will be immersed in a solution of cryopreservation beforehand prepared, then put down in a freezer in -70°C during a minimum of 24 hours before being immersed in the liquid nitrogen.
The measures of trhombinography will be realized at the rate of an analysis every other week, adaptable periodicity according to the number of recruitment made during the period.
- Conditions
- Dental Disease
- Being tested
- bone removal
- Medical subject headings
- Stomatognathic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bone removalOther
| Study group | Role | What they receive |
|---|---|---|
| bone donors | Not described Receives: Other: bone removal |
What is being measured
The primary outcome is the main question the study is designed to answer.
thrombin quantification
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2016 (estimated)
- Study startMay 2013
- Primary completionDec 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dental DiseaseStudies of the same condition, open and under way.
- More trials run by CHU de ReimsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- CHU de Reims
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02814799
- Sponsor's protocol ID
- PJ12077
- Status last verified
- Jun 2016
- First submitted
- 21 Jun 2016
- Last updated
- 28 Jun 2016
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Effects of the Bone Tissue on the Generation of Thrombine
- ClinicalTrials.gov ID
- NCT02814799
- Acronym / sponsor ID
- PJ12077
- Conditions
- Dental Disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- CHU de ReimsUniversity, hospital or other
- Study start
- May 2013
- Primary completion
- Dec 2016 (estimated)
- First posted
- 28 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The research for a haemostasis and for an effective osseous healing are a major stake in oral surgery. The use of glues of fibrin, amplifying the polymerization of the fibrin during the haemostasis is known to reduce the risk of post-operative bruise and accelerate the healing but these glues present the inconvenience to be by-products of the blood, not devoid of infectious risk.
Detailed description
Thrombinography is a functional exploration of the haemostasis allowing the characterization of the kinetics and the amount of thrombin. Its principle bases on the recording of the activity of the in vitro thrombin, by fluorometry. The formed thrombin leads a signal by activation of the fluorogenic substrates. The intensity of the received signal is correlated in the generation of thrombin by comparative measure of the fluorescence of a standard sample of thrombinic activity known. The analysis is realized by a specific software: Thrombinoscope®. The used reactional environment is a poor Plasma in platelet (PPP).
The software defines the quantity of thrombin generated (nM) according to time (in minute) and calculate the values of:
- Lag time: latent period before the beginning of synthesis of thrombin.
- Start Tail: duration of the process.
- Peak: peak of thrombin, is the maximal rate of generated thrombin.
- ETP (Endogenous Thrombin Potential): area under the curve representing the total potential of generation of thrombin.
- Time to Peak: time required to reach the peak of thrombin. It is these values which will serve as criteria of evaluation for our study.
Osseous type
The cancellous bone is majority in the short bones and the epiphyses of the long bones. It is crisp, constituted by fine osseous patches arranged in a not concentric way around wide open cavities, filled with bone marrow rich in cells, and richly vascularized. The cancellous bone is surrounded with compact bone. At the level of tooth sockets, this osseous type is found in particular at the level of interradicular septa.
The compact bone establishes the cortical. It is dense, consisted of systems of Havers. Every system is formed by a reduced central channel containing some vascularized connective tissue, and thick, concentric osseous small strips, in and between which prepares ostéocytes. This osseous type is situated at the alveolar level in the external part.
Inhibitors
To verify the possible ways involved in the thrombin formation, the investigators shall use specific inhibitors of these likely ways of activation:
- An inhibitor of the extrinsic way of the coagulation: an antibody anti tissue factor.
- An inhibitor of the intrinsic way of the coagulation: the bovine aprotinin.
- An inhibitor of phospholipids: the annexin V. Methodology of the Research
Plan of investigation
- Information of the eligible patients for the study (patients requiring dental extractions with bone removal) concerning the methods and the objectives of the research by means of the information note.
- If the patient agrees to participate in the study, realization of osseous takings and conditioning of the osseous takings for freezing in the liquid nitrogen.
- Put in touch by the osseous takings with some plasma (from pools of plasma used in laboratory for the calibration of the various automatous) and measure of the genesis of thrombin by thrombinography.
To make this measure, the osseous fragments will be put down at the bottom of the wells of the microplate then 10µL of buffer HBS will be added. The fragmentation of the osseous takings will be realized by means of a sterile material and by limiting the time of manipulation except environment.
Every sample will be handled triplicate there. Two wells will be dedicated to the standard thrombin (20µL). Two controls will be used: - positive control: 10µL of tissue factor, in the concentration of 1 or 5 pM and 10µL of PPL in the dilution of 1/100 will be used.
- Negative control: 20µL of physiological salt solution will be used. Eighty microliters of plasma are going to be put down in each of the wells. Fifty microliters of fluorescent substratum will be added to the mixture buffer - substratum fluorogenic beforehand prepared and the device is going to distribute 20µL some mixture in each of the wells, thus containing in the end 120µL.
The measures were made every 20 seconds during 60 minutes by the Fluoroskan Ascent Reader. The Thrombinoscope softwar® (Version 3.0.0.29, Maastricht) converts the intensity of fluorescence nM of thrombin according to the time.
The results of the measures will be grouped in cancellous bone, compact bone, control FT1pM, control FT5pM and secondarily averaged.
According to the obtained results, samples (compact and\or cancellous) positive for the genesis of thrombin will be analyzed in the presence of specific inhibitors of the various possible ways of activation of the coagulation. Calibrations will be made to choose the most appropriate concentration in inhibitors.
Logistics of the study
An information concerning the objectives and the modalities of the study will be given to every patient benefiting from one or several dental extractions with bone removal. If the patient agrees to participate in the study (oral agreement), the osseous taking, associated automatically with the dental extraction will be kept.
After taking, the osseous fragments will be immersed in a solution of cryopreservation beforehand prepared, then put down in a freezer in -70°C during a minimum of 24 hours before being immersed in the liquid nitrogen.
The measures of trhombinography will be realized at the rate of an analysis every other week, adaptable periodicity according to the number of recruitment made during the period.
Study design
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| bone donors | – | Other: bone removal |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The inclusive patients will be all the patients requiring dental extractions with bone removal, taken care in the department of odontology of the CHU of Reims and agreeing to participate in the study. Only these patients form the group of observed patients. The duration of participation of the patient in the study is punctual, the time of the osseous taking.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bone removal | Other | bone donors |
Primary outcome
thrombin quantification
Time frame: Day 1
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jun 2016.
Related trials for Dental Disease
RecruitingPhase 4
Hematological Safety of Dipyrone Versus Paracetamol After Dental Extractions
Hematologic Test, Agranulocytosis
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Not yet recruiting
Free Soft Tissue Grafts (FSTG) Using Autograft Palatal Donor Tissue vs. Xenograft Collagen Matrix (Zderm™)
Gingival Recession Localized Moderate, Dental Implant
Not yet recruiting
Safety Assessment of Placing a Single Dental Implant Without Antibiotic Prophylaxis in Simple Cases: A Pilot Study
Tooth Loss and Rehabillitation, Dental Implant Failure
Active, not recruiting
L-PRF Block vs Composite Graft for Horizontal Ridge Augmentation
Alveolar Ridge Resorption After Extraction, Alveolar Bone Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sébastien LAURENCE contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dental Disease, run by CHU de Reims at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Sébastien LAURENCE (sebastien.laurence@univ-reims.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
thrombin quantification (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jun 2016.